Related Experiment Video

Updated: Jul 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia

Linda Hanssens1, Marc De Hert, Dita Kalnicka

  • 1Department of Epidemiology and Public Health, Nutrition and Metabolic Disorders CHU Sart Tilman, University Liege, Liege, Belgium.

International Clinical Psychopharmacology
|December 13, 2006
PubMed

Insights

Statin therapy effectively lowers cholesterol in patients with schizophrenia, reducing cardiovascular risk. However, it only impacts triglyceride levels within metabolic syndrome, indicating a need for broader treatment strategies.

Area of Science:

  • Cardiology
  • Psychiatry
  • Pharmacology

Background:

  • Patients with schizophrenia exhibit doubled mortality rates, primarily due to cardiovascular disease.
  • Cardiovascular disease prevention in this population is critical, with low-density lipoprotein cholesterol management as a key target.

Purpose of the Study:

  • To evaluate the efficacy of lipid-lowering statin therapy in patients with schizophrenia and severe dyslipidemia.
  • To assess the impact of statins on lipid profiles, glucose metabolism, and metabolic syndrome components.

Main Methods:

  • A cohort of 46 patients with schizophrenia on antipsychotics and with severe dyslipidemia was identified.
  • Cardiovascular risk factors were screened, and statin therapy was initiated.
  • Lipid profiles, glucose homeostasis, and metabolic syndrome components were evaluated at baseline and after 3 months.

Main Results:

  • Statin therapy significantly reduced triglycerides, total cholesterol, LDL cholesterol, non-HDL cholesterol, and associated cholesterol ratios.
  • No significant changes were observed in HDL cholesterol, body mass index, waist circumference, or glucose homeostasis.
  • Serum triglyceride levels were the only metabolic syndrome component significantly affected by statin therapy.

Conclusions:

  • Statins are effective in managing dyslipidemia in schizophrenia patients receiving antipsychotic treatment.
  • Comprehensive management strategies are necessary to address other metabolic disturbances associated with schizophrenia and its treatment.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...